Recent governmental actions endanger the controversial 340B drug pricing program, even though a powerful congressional committee called the 340B program important, despite its flaws. Yet, none of the actions—from the introduction of new legislation to Medicare payment cuts—address the oversight and administrative weaknesses highlighted by the committee.
The House Energy and Commerce Committee (E&C) issued a report identifying 340B as an “important program